Delving into the Latest Updates on SL VaxiGen, Inc. with Synapse

Overview

Basic Info

Introduction

SL VaxiGen, Inc., founded on March 3, 2017, is a research and development firm specializing in the creation of vaccine therapeutics using complementary platforms aimed at saving lives. It's headquarters are located in Seongnam, South Korea.

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

DNA vaccine

Therapeutic vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	4
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

DNA vaccine	4
Therapeutic vaccine	2

Waning vaccine-induced immunity, coupled with the emergence of SARS-CoV-2 variants, has inspired the widespread implementation of COVID-19 booster vaccinations. Here, we evaluated the potential of the GX-19N DNA vaccine as a heterologous booster to enhance the protective immune response to SARS-CoV-2 in mice primed with either an inactivated virus particle (VP) or an mRNA vaccine. We found that in the VP-primed condition, GX-19N enhanced the response of both vaccine-specific antibodies and cross-reactive T Cells to the SARS-CoV-2 variant of concern (VOC), compared to the homologous VP vaccine prime-boost. Under the mRNA-primed condition, GX-19N induced higher vaccine-induced T Cell responses but lower antibody responses than the homologous mRNA vaccine prime-boost. Furthermore, the heterologous GX-19N boost induced higher S-specific polyfunctional CD4⁺ and CD8⁺ T cell responses than the homologous VP or mRNA prime-boost vaccinations. Our results provide new insights into booster vaccination strategies for the management of novel COVID-19 variants.

01 May 2020·Antiviral ResearchQ2 · MEDICINE

Multivalent DNA vaccine protects against genital herpes by T-cell immune induction in vaginal mucosa

Q2 · MEDICINE

Article

Author: Lee, Sung Ki ; Lee, Heung Kyu ; Oh, Ji Eun ; Yoo, Hye Jee ; Kwon, Myeong Seung ; Jang, Hye Seon ; Oh, Dong Sun ; Shin, Jua ; Park, Jang Hyun ; Kim, Hyeon Cheol ; Seo, Yong Bok ; Kim, Hyun-Jin ; Kim, Chae Won ; Jin, Hyun-Tak

Genital herpes is one of the most common sexually transmitted infections (STIs), and it is mainly caused by the neurotropic herpes simplex virus (HSV-2). Not only does this infection cause ulcers, but HSV-2 can also stay in a latent state in the nervous system of the host throughout their lifespan. As a result, many people do not know that they harbor this infection. Moreover, HSV-2 serves as a major risk factor for human immunodeficiency virus (HIV) infection and can be transmitted to the fetus. Despite the high risk of infection and adverse effects, attempts at development of an effective vaccine for HSV-2 have not yet been successful. In this study, we developed a DNA vaccine for HSV-2 (SL-V20). This multivalent DNA vaccine effectively reduced the pathological symptoms of infection and induced efficient elimination of the virus in a mouse model. Intramuscular injection of SL-V20 led to induction of an HSV-2-specific T-cell response in the vagina, the major infection site, and in draining lymph organs. Dendritic cells (DCs), especially basic leucine zipper ATF-like transcription factor 3 (Baft3)⁺ DCs and partially interferon regulatory factor 4 (Irf4)⁺ DCs, were involved in this T-cell-mediated protective response, while B cells were dispensable for these prophylactic effects. This study demonstrates that SL-V20 offers a novel and effective vaccine against vaginal HSV-2 infection and may be applicable to patients, pending validation in clinical studies.

Marked enhancement of neutralizing antibody and IFN-γ T-cell responses by GX-19N DNA booster in mice primed with inactivated vaccine

Author: Young Chul Sung ; Juyoung Na ; Yong Bok Seo ; You Suk Suh ; Ji In Ryu ; Duckhyang Shin

SummaryIn response to the COVID-19 pandemic, an unprecedented level of vaccine development has occurred. As a result, various COVID-19 vaccines have been approved for use. Among these, inactivated virus particle (VP) vaccines have been widely used worldwide, but additional vaccination strategies are needed because of the short duration of immune responses elicited by these vaccines. Here, we evaluated homologous and heterologous prime–boost regimens using a VP vaccine and GX-19N DNA vaccine for their ability to enhance the protective immune response against SARS-CoV-2. We demonstrated that a heterologous prime–boost regimen with the VP vaccine and GX-19N DNA vaccine resulted in enhanced SRBD- & N-specific antibody responses, compared to the homologous VP vaccine prime–boost vaccination. In addition, the neutralizing antibody response was significantly improved with the heterologous VP prime–DNA boost regimen, and the neutralizing antibody induced with the heterologous prime–boost regimen did not decrease against the SARS-CoV-2 variant of concern (VOC). The heterologous VP prime–DNA boost regimen not only significantly increased S- and N-specific IFN-γ T-cell responses, but also induced an equivalent level of T-cell response against SARS-CoV-2 VOCs. Our results provide new insights into prophylactic vaccination strategies for COVID-19 vaccination.

100 Deals associated with SL VaxiGen, Inc.

Login to view more data

100 Translational Medicine associated with SL VaxiGen, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

Phase 1 Clinical

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SL-T10	Metastatic castration-resistant prostate cancer More	Phase 1
SL-T20	Head and Neck Neoplasms More	Preclinical
SL-T30	Extranodal NK-T-Cell Lymphoma More	Preclinical
SL-N100	Neoplasms More	Preclinical
SL-V10(SL VaxiGen, Inc.)	Cytomegalovirus Infections More	Pending